Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer.

Evofosfamide, a prodrug, is unique in that it is activated in areas of the tumor that lack oxygen, said Philip. It then releases bromo isophosphoramide mustard (Br-IPM), a potent DNA alkylating agent. This kills tumor cells by forming DNA crosslinks, rendering cells unable to replicate their DNA and divide as well as interfering with the transcription of DNA to make essential proteins.

A pilot trial of evofosfamide in pancreatic cancer showed evidence of activity when it was added to gemcitabine compared to gemcitabine alone. That led to a large phase III trial that has completed accrual. Results are expected for late this year or early next year, said Philip.

View more from the 2015 World GI Congress

Videos

Philip Philip MD, PhD, professor of oncology at Karmanos Cancer Center, Wayne State University School of Medicine, discusses the use of the investigational drug evofosfamide for pancreatic cancer. 


Philip Philip MD, PhD

Articles

Dr. Philip on Evofosfamide for Pancreatic Cancer